A new treatment may prolong the lifespan of melanoma patients.
Vemurafenib, the first acute melanoma drug in more than a decade, was approved by Australian regulators last year after tests showed tumours either shrank or ceased growing.
The study found that the median lifespan of melanoma patients who received the drug was 16 months, compared with the average survival rate of advanced sufferers of six to 10 months.
Read more at The New England Journal of Medicine